<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022009</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068683</org_study_id>
    <secondary_id>CHNT-GEM</secondary_id>
    <secondary_id>EU-20062</secondary_id>
    <nct_id>NCT00022009</nct_id>
  </id_info>
  <brief_title>Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Randomized Trial Comparing Two Treatment Schedules Of Gemcitabine In Poor Prognosis Status Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Treatment plus supportive care may improve quality of life in&#xD;
      patients undergoing cancer treatment.&#xD;
&#xD;
      PURPOSE: Randomized phase II/III trial to compare the effect of different gemcitabine&#xD;
      regimens plus supportive care on quality of life in patients who have locally advanced or&#xD;
      metastatic non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare quality of life, in terms of the degree of symptom palliation and improvements&#xD;
           in performance status, of patients with locally advanced or metastatic poor prognosis&#xD;
           non-small cell lung cancer treated with 2 schedules of gemcitabine combined with best&#xD;
           supportive care.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the response rate in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of&#xD;
      2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine IV over 30 minutes once a week for 3 weeks.&#xD;
           Treatment continues every 4 weeks for 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine IV over 30 minutes once a week for 2 weeks.&#xD;
           Treatment continues every 3 weeks for 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients on both arms also receive best supportive care. Additional courses of gemcitabine&#xD;
      may be administered at the discretion of the investigator.&#xD;
&#xD;
      Quality of life is assessed at baseline and then after each course of chemotherapy.&#xD;
&#xD;
      Patients are followed every 2 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 174 patients (87 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2001</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven locally advanced or metastatic non-small cell&#xD;
             lung cancer that is not amenable to curative surgery or radiotherapy&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
          -  No concurrent cord compression or superior vena cava syndrome requiring immediate&#xD;
             radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 40-70%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 4 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 3 times normal&#xD;
&#xD;
          -  ALT and AST no greater than 3 times normal (5 times normal if liver metastasis&#xD;
             present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after study&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other concurrent serious, systemic disorder that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent steroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent palliative radiotherapy allowed&#xD;
&#xD;
          -  No concurrent curative radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent palliative surgery allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Thatcher, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christie Hospital N.H.S. Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>June 11, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

